BR112016004768A8 - Anticorpos igm de cadeia constante, biespecíficos, penta e hexavalentes modificados - Google Patents

Anticorpos igm de cadeia constante, biespecíficos, penta e hexavalentes modificados

Info

Publication number
BR112016004768A8
BR112016004768A8 BR112016004768A BR112016004768A BR112016004768A8 BR 112016004768 A8 BR112016004768 A8 BR 112016004768A8 BR 112016004768 A BR112016004768 A BR 112016004768A BR 112016004768 A BR112016004768 A BR 112016004768A BR 112016004768 A8 BR112016004768 A8 BR 112016004768A8
Authority
BR
Brazil
Prior art keywords
bispecific
igm antibodies
hexavalent
constant chain
modified penta
Prior art date
Application number
BR112016004768A
Other languages
English (en)
Other versions
BR112016004768B1 (pt
BR112016004768A2 (pt
Inventor
Keyt Bruce
Zhang Fen
George Presta Leonard
Yoshimura Rency
Original Assignee
Igm Biosciences Inc
Igm Biosciences As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc, Igm Biosciences As filed Critical Igm Biosciences Inc
Publication of BR112016004768A2 publication Critical patent/BR112016004768A2/pt
Publication of BR112016004768A8 publication Critical patent/BR112016004768A8/pt
Publication of BR112016004768B1 publication Critical patent/BR112016004768B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICORPOS IGM DE CADEIA CONSTANTE, BIESPECÍFICOS, PENTA E HEXAVALENTES MODIFICADOS. A presente invenção refere-se a moléculas de ligação com uma estrutura em anel pentamérica ou hexamérica, tais como, por exemplo, anticorpos IgM isolados com cinco ou seis unidades de ligação biespecíficas, e a métodos e meios para produção e uso dos mesmos. A invenção também se refere a moléculas de ligação multi-específicas com uma estrutura em anel pentamérica ou hexamérica, tais como, por exemplo, anticorpos IgM isolados com cinco ou seis unidades de ligação biespecíficas, e a métodos e meios para produção e uso dos mesmos.
BR112016004768-0A 2013-09-05 2014-09-04 Moléculas de ligação com uma estrutura em anel pentamérica ou hexamérica BR112016004768B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361874277P 2013-09-05 2013-09-05
US201361874284P 2013-09-05 2013-09-05
US61/874,284 2013-09-05
US61/874,277 2013-09-05
PCT/US2014/054079 WO2015053887A1 (en) 2013-09-05 2014-09-04 Constant chain modified bispecific, penta- and hexavalent ig-m antibodies

Publications (3)

Publication Number Publication Date
BR112016004768A2 BR112016004768A2 (pt) 2017-09-05
BR112016004768A8 true BR112016004768A8 (pt) 2018-06-12
BR112016004768B1 BR112016004768B1 (pt) 2023-07-11

Family

ID=

Also Published As

Publication number Publication date
US10351631B2 (en) 2019-07-16
JP6721505B2 (ja) 2020-07-15
JP2016531924A (ja) 2016-10-13
AU2014332458A1 (en) 2016-04-07
CN105722855A (zh) 2016-06-29
US20160222132A1 (en) 2016-08-04
KR20160077036A (ko) 2016-07-01
BR112016004768A2 (pt) 2017-09-05
EP3041862B1 (en) 2020-05-06
CA2922830A1 (en) 2015-04-16
CN105722855B (zh) 2021-04-23
WO2015053887A1 (en) 2015-04-16
EP3041862A1 (en) 2016-07-13
KR102306492B1 (ko) 2021-09-29
DK3041862T3 (da) 2020-07-27
AU2014332458B2 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
CY1122478T1 (el) Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη
AU2019268150A1 (en) Isotyping immunoglobulins using accurate molecular mass
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
WO2019126514A3 (en) Antibodies to lilrb2
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
EP3702372A3 (en) Anti-cd40 human antibodies
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EP3268308B8 (en) Method and system for the manufacture of methane, heat and electricity by hydrogasification of biomass
EP4420727A3 (en) Bispecific egfr/c-met antibodies
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
CR20130376A (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
NZ799532A (en) Methods and means for the production of ig-like molecules
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
BR112016011983A2 (pt) Painel, painel laminado, arranjo de painel, método para produzir o painel e uso do painel
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CO7151529A2 (es) Anticuerpos anti-cd22 e inmunoconjugados
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EP3041499A4 (en) Reagents and methods for screening mps i, ii, iiia, iiib, iva, vi, and vii

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IGM BIOSCIENCES A/S (DK)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B25A Requested transfer of rights approved

Owner name: IGM BIOSCIENCES, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2014, OBSERVADAS AS CONDICOES LEGAIS